Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

L'Oreal ready to buy Nestle stake in cosmetics leader

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 03:41pm CET
FILE PHOTO: Bottles of shampoos, conditioners and color spray are displayed at cosmetics company L'Oreal's new World hair research centre in Saint-Ouen near Paris

PARIS (Reuters) - L'Oreal (>> L'Oréal) on Friday underscored its readiness to buy Nestle's (>> Nestlé) 23 percent stake in the world's biggest cosmetics firm were its Swiss shareholder to sell, saying it had access to cash and funding at its disposal.

PARIS (Reuters) - L'Oreal (>> L'Oréal) on Friday underscored its readiness to buy Nestle's (>> Nestlé) 23 percent stake in the world's biggest cosmetics firm were its Swiss shareholder to sell, saying it had access to cash and funding at its disposal.

L'Oreal said it could finance a purchase of the holding, now worth around 22.3 billion euros (19.64 billion pounds), with cash, by selling its stake in French drugmaker group Sanofi (>> Sanofi) or through borrowing if needed.

"If Nestle one day wants to sell, we are ready," Chairman and Chief Executive Jean-Paul Agon told a news conference, after L'Oreal released slightly better-than-expected fourth-quarter earnings.

The death of L'Oreal heiress Liliane Bettencourt last September set the clock ticking on the end of 44-year-old shareholder pact between the French company's founding family and Nestle.

The agreement prevented the Bettencourts, which have 33 percent of L'Oreal, and the Swiss food group from raising their holdings. It is now set to expire in mid-March, stirring speculation over the shareholders' relationship and whether Nestle might sell out or even contemplate a takeover.

Nestle had previously been at liberty to whittle down its L'Oreal holding, however, and has yet to budge, in spite of pressure from activist investor Daniel Loeb, founder of hedge fund Third Point. Loeb has pushed for a sale among demands for the Swiss firm to speed up a strategy overhaul.

"We have 1.8 billion euros in cash, we have the Sanofi stake. We are also a very serious and loyal and active shareholder in Sanofi, but in case we will be ready and I'm sure if it was not enough, we have many love letters from banks that have said that they would love to lend us some money," Agon said.

Nestle and Sanofi declined to comment. Shares in L'Oreal, maker of Garnier shampoo and cosmetics labels like Lancome, were up 1.3 percent at 1413 GMT, among the top gainers on France's blue-chip CAC-40 <.FCHI> index. Nestle shares were up 0.6 percent, while Sanofi was 0.9 percent lower.

NO CHANGE

Nestle has so far given no signs it could sell out of L'Oreal.

"Our approach to this investment is currently not changing," Nestle CEO Mark Schneider told investors in September.

The L'Oreal stake is worth about 10 percent of Nestle's market capitalisation and has contributed to its earnings, but some investors, including Loeb, think that money could be put to better use.

Loeb has praised Nestle's chief for other recent steps such as buying back stock, buying and selling some assets and bringing new directors onto the board.

Others say that Nestle should keep the stake until it has something else in mind to buy.

Nestle was interested in the vitamin and supplements business being sold by Merck (>> Merck KGaA), but has dropped out of the running.

L'Oreal already bought an 8 percent stake in the firm from Nestle in 2014, and cancelled the shares. That 6.5 billion-euro deal allowed both companies to boost their earnings per share.

Buying the remaining 23 percent could be positive for L'Oreal, some analysts said.

"This may excite some: an acquisition of the stake by L'Oreal, part-funded by a sale of its own Sanofi stake would be circa 10 percent accretive," Investec Securities analysts said in a note.

At today's stock price, L'Oreal's 9 percent stake in Sanofi - a legacy from its incursion into the pharmaceuticals business in 1973, before the modern day Sanofi was formed - is worth more than 7 billion euros, according to Reuters data.

L'Oreal's Agon said on Thursday he was confident of significant growth in like-for-like sales in 2018. The company, whose brand ambassadors include Helen Mirren, Eva Longoria and Blake Lively, was boosted last year by strong sales in Asia and demand for its luxury products.

(Reporting by Dominique Vidalon, Sarah White, Martinne Geller, Matthias Blamont and Pascale Denis; Editing by Alexander Smith and David Evans)

By Sarah White and Dominique Vidalon

Stocks treated in this article : L'Oréal, Sanofi, Merck KGaA, Nestlé
Valeurs citées dans l'article
ChangeLast1st jan.
L'ORÉAL -0.92% 172.6 Real-time Quote.-5.70%
NESTLÉ -0.51% 74.7 Delayed Quote.-10.45%
SANOFI -0.40% 64.39 Real-time Quote.-9.95%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
02/21MERCK : to Invest Additional EUR40 Million in Asia
DJ
02/21MERCK : Darmstadt, Germany Invests Additional $47 Million to Enhance Manufacturi..
PU
02/21BIOLOGICS SAFETY TESTING MARKET : Increase in Biotechnology and Pharmaceuticals ..
AQ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/20MERCK : The Life Science Business of Merck KGaA, Darmstadt, Germany to Receive T..
PU
02/20MERCK : Darmstadt, Germany, and Three Partners Start ExploreBio, a € 20 million ..
PU
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19GLYCOBIOLOGY MARKET 2017 TO 2025 BY : Agilent Technologies Inc, Waters Corporat..
AQ
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
AQ
02/16MERCK : Darmstadt, Germany, Named One of the Global Top Employers in 2018
PU
More news
News from SeekingAlpha
02/21Merck KGaA to beef up manufacturing and distribution in Asia 
02/203 THINGS IN BIOTECH YOU SHOULD LEARN : February 19, 2018 
02/13BioLife inks supply agreement with MilliporeSigma; shares up 4% 
02/02Nestle backs away from Merck KGaA's consumer unit 
01/10Nestle frontrunner for Merck KGaA's consumer health unit 
Financials (€)
Sales 2017 15 336 M
EBIT 2017 3 358 M
Net income 2017 1 697 M
Debt 2017 9 767 M
Yield 2017 1,55%
P/E ratio 2017 17,81
P/E ratio 2018 18,73
EV / Sales 2017 1,33x
EV / Sales 2018 1,19x
Capitalization 10 642 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 107 €
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-8.26%13 053
ABBVIE21.99%188 235
KYOWA HAKKO KIRIN CO LTD2.03%12 154
JAZZ PHARMACEUTICALS PLC7.52%8 716
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 873
CONVATEC GROUP2.68%5 763